MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy.

Mol Pharm

Research Center of oils and fats, Food and Drug Administration, Kermanshah University of Medical sciences, Kermanshah, Iran.

Published: May 2021

Mucin 1 (MUC1) is a large, transmembrane mucin glycoprotein overexpressed in most adenocarcinomas and plays an important role in tumor progression. Regarding its cellular distribution, biochemical features, and function, tumor-related MUC1 varies from the MUC1 expressed in normal cells. Therefore, targeting MUC1 for cancer immunotherapy and imaging can exploit the difference between cancerous and normal cells. Radiopharmaceuticals have a potential use as carriers for the delivery of radionuclides to tumors for a diagnostic imaging and radiotherapy. Several radiolabeled targeting molecules like peptides, antibodies, and aptamers have been efficiently demonstrated in detecting and treating cancer by targeting MUC1. This review provides a brief overview of the current status of developments and applications of MUC1-targeted radiopharmaceuticals in cancer imaging and therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.0c01249DOI Listing

Publication Analysis

Top Keywords

muc1-targeted radiopharmaceuticals
8
radiopharmaceuticals cancer
8
cancer imaging
8
imaging therapy
8
normal cells
8
targeting muc1
8
muc1
5
cancer
4
imaging
4
therapy mucin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!